albumin - publications

Predict more albumin - ligand interactions now!

1. Diabetes Obes Metab. 2012 Jan 23. doi: 10.1111/j.1463-1326.2012.01566.x. [Epub
ahead of print]

Randomized comparison of pitavastatin and pravastatin treatment on the reduction
of urinary albumin in patients with type 2 diabetic nephropathy.

Kimura S, Inoguchi T, Yokomizo H, Maeda Y, Sonoda N, Takayanagi R.

Department of Medicine and Bioregulatory Science, Graduate School of Medical
Sciences, Kyushu University, Fukuoka, Japan Innovation Center for Medical Redox
Navigation, Kyushu University, Fukuoka, Japan;

The effect of pitavastatin and pravastatintreatment on renal function was
compared in type 2 diabetes patients with nephropathy in a randomized,
controlled, open-label, parallel and multi-center study.Type 2 diabetic patients
with modest renal impairment (serum creatinine level<1.4 mg/dL) accompanied by
albuminuria (30-600mg/g creatinine) were randomly assigned to receive 2 mg of
pitavastatin (n = 44) or 10 mg of pravastatin (n =43) for 12 months. At 12
months,pitavastatin significantly reduced urinary albumin-to-creatinine ratio
than pravastatin in subjects with macroalbuminuria (-67.2 % vs. +14.5%,P =
0.0040), but not in subjects with microalbuminuria. There was no significant
difference in the change in estimated glomerular filtration rate (eGFR)between
two groups.Pitavastatin is more effective than pravastatin for the reduction of
albuminuria in type 2 diabetic patients with early stage of diabetic nephropathy.

© 2012 Blackwell Publishing Ltd.

PMID: 22268518 [PubMed - as supplied by publisher]